CBD represents the first nontoxic exogenous agent that can significantly decrease Id-1 expression in metastatic breast cancer cells leading to the down-regulation of tumor aggressiveness. In 2007, at the California Pacific Medical Center Research Institute, a study was published by Sean McAllister in the journal Molecular Cancer Therapeutics titled: Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.
About The SCC
Beyond THC Survey
The SCC has developed a CBD-rich cannabis survey because physicians need to know what patients are experiencing. Are the effects of CBD-rich cannabis and high-THC cannabis noticeably different? If so, how? Patients, collectively, can provide the answers. Learn more...